865468-78-6

Basic information

• Product Name: ethyl 1-((benzyloxy)methyl)-4,4-difluorocyclohexane-1-carboxylate
• Synonyms: ethyl 1-((benzyloxy)methyl)-4,4-difluorocyclohexane-1-carboxylate
• CAS NO: 865468-78-6
• Molecular Weight: 312.357
• Mol File: 865468-78-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: ethyl 1-((benzyloxy)methyl)-4,4-difluorocyclohexane-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 1-((benzyloxy)methyl)-4,4-difluorocyclohexane-1-carboxylate(865468-78-6)
• EPA Substance Registry System: ethyl 1-((benzyloxy)methyl)-4,4-difluorocyclohexane-1-carboxylate(865468-78-6)

Safety Data

• Hazardous Substances Data: 865468-78-6(Hazardous Substances Data)

Upstream product

• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 178312-47-5 ethyl 4,4-difluorocyclohexane-1-carboxylate 
• 3587-60-8 Benzyloxymethyl chloride 

Downstream Products

• 1447942-27-9 ethyl 4,4-difluoro-1-(methoxymethyl)cyclohexane carboxylate 
• 1447942-24-6 4,4-difluoro-1-(fluoromethyl)cyclohexanecarboxylic acid 
• 1447942-25-7 ethyl 4,4-difluoro-1-(fluoromethyl)cyclohexanecarboxylate 
• 1447942-23-5 4,4-difluoro-1-(hydroxymethyl)cyclohexane-1-carboxylic acid 
• 865468-79-7 ethyl 4,4-difluoro-1-(hydroxymethyl)cyclohexanecarboxylate 

Relevant articles and documents

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.